PMID: 6965578Feb 1, 1980Paper

Penetration characteristics of cefamandole into the right atrial appendage and pericardial fluid in patients undergoing open-heart surgery

The Annals of Thoracic Surgery
N H OlsonR Quintiliani

Abstract

In 24 patients undergoing open-heart operation, 2 gm of cefamandole was administered intravenously by bolus technique at various time intervals prior to operation. Samples of pericardial fluid, atrial appendage tissue, and serum were obtained simultaneously in order to compare antibiotic levels in these sites as a function of time. All samples were microbiologically assayed by disc diffusion. Using linear regression analysis, the atrial appendage and serum half-lives for cefamandole were 36 and 38 minutes, respectively. At 40 minutes, peak levels of cefamandole were observed both in pericardial fluid and in atrial appendage tissue. The peak concentrations of cefamandole were 50 micrograms/gm in atrial appendage and 25 micrograms/ml for free drug content in pericardial fluid. These amounts were appreciably above the mean minimum inhibitory concentration of cefamandole for penicillin-resistant staphylococci, the usual pathogens grown in infections following implant operation.

References

Oct 1, 1977·Southern Medical Journal·P D MyerowitzD M Nicoloff
May 1, 1978·The Journal of Infectious Diseases·B R Meyers, S Z Hirschman
Jun 1, 1978·Antimicrobial Agents and Chemotherapy·G L ArcherR Lower
May 1, 1978·The Journal of Infectious Diseases·H C Neu
Feb 1, 1977·Antimicrobial Agents and Chemotherapy·H E MellinP O Madsen
Nov 1, 1977·Journal of Pharmaceutical Sciences·D S GreeneC H Nightingale
Jun 1, 1976·Antimicrobial Agents and Chemotherapy·T C Eickhoff, J M Ehret
Nov 1, 1976·Clinical Pharmacology and Therapeutics·W E GroseD Stewart
Nov 1, 1976·Antimicrobial Agents and Chemotherapy·R S GriffithJ D Wolny
Dec 1, 1975·Antimicrobial Agents and Chemotherapy·N K ShemonskyM E Levison
Jan 1, 1976·Antimicrobial Agents and Chemotherapy·B R MeyersS Z Hirschman
Jan 1, 1976·Antimicrobial Agents and Chemotherapy·I W FongW M Kirby
Nov 26, 1973·Annals of the New York Academy of Sciences·C M KuninR Monson
Jan 18, 1968·The New England Journal of Medicine·J S GoodmanM G Koenig

❮ Previous
Next ❯

Citations

Sep 1, 1990·Antimicrobial Agents and Chemotherapy·M G BergeronC Lessard
Jun 1, 1982·Current Problems in Surgery·S H Dougherty, R L Simmons
Mar 15, 2015·Biopharmaceutics & Drug Disposition·Zofia Tylutki, Sebastian Polak
Aug 1, 1987·Journal of the Royal Society of Health·E A Houlton
Feb 1, 1983·Current Problems in Surgery·J T DipiroW O Griffen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.